

Sitanshu S Singh

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8684683/sitanshu-s-singh-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22
papers

197
citations

9
h-index

13
g-index

24
ext. papers

306
ext. citations

4.8
avg, IF

3.58
L-index

#	Paper	IF	Citations
22	Targeting protein-protein interaction for immunomodulation: A sunflower trypsin inhibitor analog peptidomimetic suppresses RA progression in CIA model. <i>Journal of Pharmacological Sciences</i> , 2022 , 149, 124-138	3.7	
21	A pH-sensitive liposome formulation of a peptidomimetic-Dox conjugate for targeting HER2 ⁺ cancer.. <i>International Journal of Pharmaceutics</i> , 2021 , 612, 121364	6.5	2
20	Mini-Review: PDPK1 (3-phosphoinositide dependent protein kinase-1), An Emerging Cancer Stem Cell Target. <i>Journal of Cancer Treatment & Diagnosis</i> , 2021 , 5, 30-35	2.1	1
19	A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models. <i>European Journal of Medicinal Chemistry</i> , 2021 , 216, 113312	6.8	7
18	Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment. <i>Journal of Controlled Release</i> , 2021 , 329, 624-644	11.7	15
17	Lipidated Peptidomimetic Ligand-Functionalized HER2 Targeted Liposome as Nano-Carrier Designed for Doxorubicin Delivery in Cancer Therapy. <i>Pharmaceutics</i> , 2021 , 14,	5.2	4
16	Quinazoline-tethered hydrazone: A versatile scaffold toward dual anti-TB and EGFR inhibition activities in NSCLC. <i>Archiv Der Pharmazie</i> , 2021 , 354, e2100281	4.3	1
15	Click Conjugation of Boron Dipyrromethene (BODIPY) Fluorophores to EGFR-Targeting Linear and Cyclic Peptides. <i>Molecules</i> , 2021 , 26,	4.8	2
14	(-)-Oleocanthol as a Dual c-MET-COX2 Inhibitor for the Control of Lung Cancer. <i>Nutrients</i> , 2020 , 12,	6.7	9
13	Targeting EGFR Overexpression at the Surface of Colorectal Cancer Cells by Exploiting Amidated BODIPY-Peptide Conjugates. <i>Photochemistry and Photobiology</i> , 2020 , 96, 581-595	3.6	3
12	Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy. <i>Current Medicinal Chemistry</i> , 2020 , 27, 5274-5316	4.3	9
11	Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor. <i>Pharmacological Research</i> , 2020 , 158, 104847	10.2	16
10	studies of a peptidomimetic that targets EGFR dimerization in NSCLC. <i>Journal of Cancer</i> , 2020 , 11, 5982-5999	4.9	3
9	Fisetin, a 3,7,3',4'-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models. <i>Cells</i> , 2019 , 8,	7.9	23
8	GHRH antagonists support lung endothelial barrier function. <i>Tissue Barriers</i> , 2019 , 7, 1669989	4.3	32
7	Synthesis, Characterization, and Evaluation of Near-IR Boron Dipyrromethene Bioconjugates for Labeling of Adenocarcinomas by Selectively Targeting the Epidermal Growth Factor Receptor. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 3323-3335	8.3	19
6	Design of cyclic and d-amino acids containing peptidomimetics for inhibition of protein-protein interactions of HER2-HER3. <i>Journal of Peptide Science</i> , 2018 , 24, e3066	2.1	7

5	Peptide ligands for targeting the extracellular domain of EGFR: Comparison between linear and cyclic peptides. <i>Chemical Biology and Drug Design</i> , 2018 , 91, 605-619	2.9	10
4	Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design. <i>Advances in Protein Chemistry and Structural Biology</i> , 2018 , 111, 1-59	5.3	4
3	Proximity ligation assay to study protein-protein interactions of proteins on two different cells. <i>BioTechniques</i> , 2018 , 65, 149-157	2.5	13
2	Design of novel lipidated peptidomimetic conjugates for targeting EGFR heterodimerization in HER2 + cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018 , 28, 3506-3513	2.9	4
1	A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization. <i>Oncotarget</i> , 2017 , 8, 74244-74262	3.3	11